1. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines
- Author
-
Rasaneh, Samira, Rajabi, Hossein, Hossein Babaei, Mohammad, and Johari Daha, Fariba
- Subjects
- *
DRUG toxicity , *BREAST cancer treatment , *TRASTUZUMAB , *CELL lines , *RADIOPHARMACEUTICALS , *CANCER cells , *RADIOIMMUNOTHERAPY , *LUTETIUM - Abstract
Abstract: In this study, we labeled trastuzumab with 177Lu to synthesize a new radiopharmaceutical for therapy of breast cancer and at the first stage investigated its therapeutic effects on SKBr3 and MCF7 breast cancer cell lines. Trastuzumab-177Lu showed very good in-vitro characteristics such as high radiochemical purity (91±0.9%), good stability in PBS buffer (86±2.3%) and blood serum (81±2.7%) up to 96h, appropriate immunoreactivity (85.4±1.1%) and high cytotoxicity in HER2 expression cells. 5 fold increase in toxicity of trastuzumab-177Lu was observed when compared with unlabeled trastuzumab on SKBr3 cells. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF